Trial Profile

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; MVA brachyury TRICOM vaccine (Primary) ; Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms AtezoVax

Most Recent Events

21 Sep 2021 Planned End Date changed from 1 Mar 2024 to 9 Apr 2021.
21 Sep 2021 Planned primary completion date changed from 1 Mar 2023 to 9 Apr 2021.21 Sep 20
14 Jul 2021 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com